Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy

Currently interferon alfa-2b (IFNα-2b) is an approved adjuvant drug for high-risk melanoma patients that leads to an improvement in disease-free survival (DFS). However, it is unclear whether it also impacts overall survival. Widespread use of adjuvant high-dose IFNα has been tempered by its signifi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Medicine (Baltimore)
Päätekijät: Kaehler, Katharina C., Blome, Christine, Forschner, Andrea, Gutzmer, Ralf, Haalck, Thomas, Heinzerling, Lucie, Kornek, Thomas, Livingstone, Elisabeth, Loquai, Carmen, Maul, Lara Valeska, Lang, Berenice M., Schadendorf, Dirk, Stade, Barbara, Terheyden, Patrick, Utikal, Jochen, Wagner, Tobias, Hauschild, Axel, Garbe, Claus, Augustin, Matthias
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wolters Kluwer Health 2016
Aiheet:
5700
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5120927/
https://ncbi.nlm.nih.gov/pubmed/27861370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000005375
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia